End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5 MYR | -1.96% | -.--% | +117.39% |
04-02 | Supergenics Seeks More Time to Complete Private Share Placement | MT |
02-29 | Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Capitalization 1 | 27.44 | 26.04 | 27.44 |
Enterprise Value (EV) 1 | 29.58 | 29.55 | 32.12 |
P/E ratio | -12.7 x | 1,284 x | 79.3 x |
Yield | - | - | - |
Capitalization / Revenue | 5.34 x | 2.37 x | 2.56 x |
EV / Revenue | 5.76 x | 2.69 x | 3 x |
EV / EBITDA | -16.7 x | 26.7 x | 18.3 x |
EV / FCF | -15,654,959 x | -28,272,519 x | -38,713,113 x |
FCF Yield | -0% | -0% | -0% |
Price to Book | 5.03 x | 4.76 x | 5.44 x |
Nbr of stocks (in thousands) | 93,000 | 93,000 | 93,000 |
Reference price 2 | 0.2950 | 0.2800 | 0.2950 |
Announcement Date | 30/04/21 | 29/04/22 | 28/04/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 5.243 | 6.656 | 11.01 | 5.135 | 10.99 | 10.72 |
EBITDA 1 | 0.5332 | 2.213 | 2.253 | -1.769 | 1.107 | 1.752 |
EBIT 1 | 0.3977 | 2.058 | 2.103 | -2.013 | 0.4625 | 1.181 |
Operating Margin | 7.59% | 30.92% | 19.1% | -39.21% | 4.21% | 11.02% |
Earnings before Tax (EBT) 1 | 0.353 | 1.987 | 1.949 | -2.374 | 0.1308 | 0.7712 |
Net income 1 | 0.3266 | 1.518 | 1.541 | -2.15 | 0.0203 | 0.3458 |
Net margin | 6.23% | 22.8% | 14% | -41.86% | 0.19% | 3.23% |
EPS 2 | 1.306 | 6.068 | 0.1532 | -0.0232 | 0.000218 | 0.003718 |
Free Cash Flow | - | 0.0632 | -1.023 | -1.89 | -1.045 | -0.8297 |
FCF margin | - | 0.95% | -9.29% | -36.8% | -9.51% | -7.74% |
FCF Conversion (EBITDA) | - | 2.86% | - | - | - | - |
FCF Conversion (Net income) | - | 4.17% | - | - | - | - |
Dividend per Share | - | - | 0.003000 | - | - | - |
Announcement Date | 13/11/19 | 13/11/19 | 08/05/20 | 30/04/21 | 29/04/22 | 28/04/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 1.52 | 1.11 | 2.9 | 2.15 | 3.51 | 4.68 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 2.849 x | 0.5014 x | 1.289 x | -1.213 x | 3.172 x | 2.674 x |
Free Cash Flow | - | 0.06 | -1.02 | -1.89 | -1.05 | -0.83 |
ROE (net income / shareholders' equity) | - | 155% | 61.4% | -49.2% | 0.37% | 7.1% |
ROA (Net income/ Total Assets) | - | 29.9% | 18.3% | -11.4% | 2.08% | 4.87% |
Assets 1 | - | 5.078 | 8.439 | 18.86 | 0.9774 | 7.097 |
Book Value Per Share 2 | 0.8900 | 6.960 | 0.0500 | 0.0600 | 0.0600 | 0.0500 |
Cash Flow per Share 2 | 0.0300 | 0.2300 | 0.0100 | 0.0200 | 0.0200 | 0 |
Capex 1 | 0.33 | 0.01 | 0.22 | 3.3 | 0.45 | 0.32 |
Capex / Sales | 6.29% | 0.22% | 2% | 64.2% | 4.1% | 3% |
Announcement Date | 13/11/19 | 13/11/19 | 08/05/20 | 30/04/21 | 29/04/22 | 28/04/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+117.39% | 12.35M | |
+1.19% | 71.93B | |
-2.18% | 56.96B | |
+22.52% | 38.62B | |
+21.83% | 32.63B | |
+12.11% | 29.24B | |
+20.42% | 21.54B | |
+11.86% | 18.87B | |
+39.66% | 17.87B | |
+75.63% | 17.65B |
- Stock Market
- Equities
- SGBHD Stock
- Financials Supergenics